Vectofusin-1 Improves Transduction of Primary Human Cells with Diverse Retroviral and Lentiviral Pseudotypes, Enabling Robust, Automated Closed-System Manufacturing

Cell and gene therapies are finally becoming viable patient treatment options, with both T cell- and hematopoietic stem cell (HSC)-based therapies being approved to market in Europe. However, these therapies, which involve the use of viral vector to modify the target cells, are expensive and there i...

Descripción completa

Detalles Bibliográficos
Autores principales: Radek, Constanze, Bernadin, Ornellie, Drechsel, Katharina, Cordes, Nicole, Pfeifer, Rita, Sträßer, Pia, Mormin, Mirella, Gutierrez-Guerrero, Alejandra, Cosset, François-loïc, Kaiser, Andrew D., Schaser, Thomas, Galy, Anne, Verhoeyen, Els, Johnston, Ian C.D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Mary Ann Liebert, Inc., publishers 2019
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6919281/
https://www.ncbi.nlm.nih.gov/pubmed/31578886
http://dx.doi.org/10.1089/hum.2019.157

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6919281/
https://www.ncbi.nlm.nih.gov/pubmed/31578886
http://dx.doi.org/10.1089/hum.2019.157

Ejemplares similares